Hollis and Grootendorst report on cost of proposed CETA patent provisions

Here's an article from the Globe and Mail about a report by Aidan Hollis (U Calgary) and Paul Grootendorst (U Toronto) released today.  The lead of the Globe article:

Provisions in a new trade deal being negotiated between Canada and the European Union could add about $2.8-billion a year in costs to Canadian drug plans if implemented, a new report warns.

The estimate includes $1.3-billion more for public drug plans and $1.5-billion for private drug plans.

The report itself is in pdf HERE.